



COVID-19 Treatment and Vaccine Tracker

This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development.

TREATMENTS

Number	Type of Product - Treatment	FDA-Approved Indications	Clinical Trials for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
ANTIBODIES										
1	Polyclonal hyperimmune globulin (H-IG), formerly known at TAK-888	N/A		Alliance among Takeda, CSL Behring, Biotest AG, Bio Products Laboratory, LFB, and Octapharma	Pre-clinical			Begin Phase 1 trials in late spring. To patients between December 2020 and December 2021		PhRMA Wall Street Journal Pink Sheet Press release from the alliance
2	Antibodies from mice, REGN3048-3051, against the spike protein	N/A		Regeneron	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)		Start Phase 1 June 2020		Stat News MarketWatch Reuters Bloomberg News FierceBiotech FiercePharma
3	Antibodies from recovered COVID-19 patients	N/A		Celltrion	Pre-clinical			Start Phase 1 in July 2020		Korea Herald UPI Celltrion press release
4	Super-antibody or antibody cocktail to target potential mutations of SARS-CoV-2	N/A		Celltrion	Pre-clinical					Celltrion press release
5	Antibodies from recovered COVID-19 patients	N/A		Kamada	Pre-clinical					BioSpace AbbVie
6	Antibodies from recovered COVID-19 patients	N/A		Vir Biotech/WuXi Biologics/Biogen	Pre-clinical			Start Phase 1 ~ July 2020		Stat News Vir Biotech Vir Biotech

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
7	VIR-7831 and VIR-7832, antibodies from recovered COVID-19 patients	N/A		Vir Biotech/GSK/Samsung	Pre-clinical			Start Phase 2 ~ July-September 2020		Vir Biotech Samsung and Vir press release
8	Antibodies from recovered COVID-19 patients	N/A		Eli Lilly/Ab-Cellera (NIH Vaccines Research Center)	Pre-clinical	Defense Advanced Research Projects Agency*		Start Phase 1 in late July 2020		Endpoints News AbCellera*
9	Avastin (bevacizumab), vascular endothelial growth factor inhibitor	FDA-approved since 2004, approved to treat certain types of cancer		Numerous trials with Chinese research sponsors; Roche	Clinical		NCT04275414 (Qilu Hospital of Shandong University) pilot study NCT04305106 (Qilu Hospital of Shandong University) investigational study			BioCentury
10	PD-1 blocking antibody; Thymosin	Unknown		Numerous trials with Chinese research sponsors	Clinical		NCT04268537 ChiCTR2000030028	Phase 2 primary trial ends April 30, 2020		BioCentury
11	leronlimab (PRO 140), a CCR5 antagonist	N/A	Treatment of HIV/AIDS, Graft versus Host Disease, Non-Alcoholic Steatohepatitis, and numerous cancers	CytoDyn	Clinical/Compassionate Use		NCT04343651 (CytoDyn, Inc.) NCT04347239 (CytoDyn, Inc.)*	Phase 2 trial started in April 2020; Phase 2b/3 trial starts April 2020	CytoDyn	Clinical Trials Arena CytoDyn CytoDyn CytoDyn CytoDyn CytoDyn
12	AiRuiKa (camrelizumab), anti-programmed cell death protein (PD-1) antibody	N/A	Treatment of certain cancers	Wuhan Jinyintan Hospital	Clinical		ChiCTR2000029806			Hengrui Medicine
13	Kevzara (sarilumab), interleukin-6 receptor antagonist	FDA-approved since 2017, approved to treat rheumatoid arthritis		Sanofi/Regeneron	Clinical	Biomedical Advanced Research and Development Authority (BARDA)	NCT04315298 NCT04321993 (Lisa Barrett, Nova Scotia Health Authority) (lopinavir/ritonavir; hydroxychloroquine; baricitinib; sarilumab)	Started Phase 2/3 in March 2020; initial data expected April 2020		FiercePharma Wall Street Journal Seeking Alpha Regeneron Reuters MedicalCountermeasures.gov

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
14	Actemra (tocilizumab), interleukin-6 receptor antagonist	FDA-approved since 2010, approved to treat various type of arthritis, including rheumatoid arthritis, and cytokine release syndrome		Numerous trials with global research sponsors; Roche	Clinical	Biomedical Advanced Research and Development Authority (BARDA)	NCT04317092 (National Cancer Institute, Naples) NCT04320615 (Roche) NCT04310228 (Peking University First Hospital) (also tocilizumab + favipiravir); ChiCTR2000030894 NCT04306705 (Tongji Hospital) (Cytokine Release Syndrome) ChiCTR2000030442 (The Second Affiliated Hospital of Xi'an Jiaotong University) (combination of Tocilizumab, IVIG and CRRT) ChiCTR2000029765 (The First Affiliated Hospital of University of Science and Technology of China [Anhui Provincial Hospital])	Roche studies begin April 2020	ChinaXiv	Wall Street Journal FiercePharma Genentech FiercePharma
15	Gimsilumab, anti-granulocyte-macrophage colony stimulating factor monoclonal	N/A		Roivant Sciences	Clinical			Phase 2 study started in April 2020*		Roivant Roivant*
16	TJM2 (TJ003234), anti-granulocyte-macrophage colony stimulating factor antibody	N/A		i-Mab Biopharma	Clinical					i-Mab Biopharma
17	lenzilumab, anti-granulocyte-macrophage colony stimulating factor antibody	N/A	Prevent cytokine storm with CAR-T cancer therapy; prevention/treatment of acute graft versus host disease; chronic myelomonocytic leukemia; eosinophilic asthma	Humanigen Inc.	Clinical / Compassionate Use					BioWorld Humanigen Humanigen Humanigen

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
18	Sylvant (siltuximab), interleukin-6 targeted monoclonal	FDA-approved since 2014, approved to treat multicentric Castleman disease		EUSA Pharma/The Papa Giovanni XXII Hospital	Clinical		NCT04322188 (A.O. Ospedale Papa Giovanni XXIII)	Interim data shared April 2020	EUSA Pharma medRxiv	EUSA Pharma
19	Soliris (eculizumab), complement inhibitor	FDA-approved since 2007, approved to treat Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, and Neuromyelitis Optica Spectrum Disorder		Alexion	Clinical/Expanded access		NCT04288713 (Hudson Medical) (expanded access trial)	Phase 2 to start in April 2020		Alexion GlobalData
20	Ilaris (canakinumab), interleukin-1beta blocker	FDA approved since 2009, approved to treat periodic fever syndromes and systemic juvenile idiopathic arthritis		Novartis	Clinical					Reuters
21	Gamifant (emapalumab), anti-interferon gamma antibody	FDA-approved since 2018, approved to treat primary hemophagocytic lymphohistiocytosis		Swedish Orphan Biovitrum	Clinical		NCT04324021 (Swedish Orphan Biovitrum), (Emapalumab; Anakinra)			
22	meplazumab, anti-CD147 antibody	N/A		Tang-Du Hospital	Clinical		NCT04275245 (Tang-Du Hospital)		medRxiv	
23	LY3127804, anti-Angiopoietin 2 (Ang2) antibody	N/A		Eli Lilly	Clinical			Phase 2 to start in April 2020		Eli Lilly
24	Antibody	N/A		Erasmus MC/Utrecht University	Pre-clinical					Erasmus Magazine bioRxiv
25	Antibodies	Unknown		ImmunoPrecise Antibodies	Pre-clinical					Clinical Trials Arena
26	Antibody	N/A		Harbour BioMed/Mount Sinai Health System	Pre-clinical					Mount Sinai and Harbour BioMed press release

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
27	Antibodies targeting the S protein from convalescent serum, humanized mice, and phage display	N/A		AstraZeneca/US Army Medical Research Institute of Infectious Diseases (USAMRIID)/University of Maryland School of Medicine	Pre-clinical			Phase 1 trials begin in summer 2020		PhRMA AstraZeneca
28	Antibody	Unknown		Distributed Bio	Pre-clinical					Distributed Bio
29	Antibodies	Unknown		Chelsea and Westminster Hospital, Imperial College London	Pre-clinical	UK Government				UK Government
30	Antibody	N/A		Vanderbilt Vaccine Center	Pre-clinical	Defense Advanced Research Projects Agency		Phase 1 trial begins in summer 2020		Nashville Post
31	Antibodies	N/A		Medicago/ Laval University's Infectious Disease Research Centre	Pre-clinical	Canadian Institutes for Health Research (CIHR)				Medicago press release
32	Polyclonal hyperimmune globulin (H-IG)	N/A	Same human hyperimmune platform as FDA-approved anthrax treatment (Anthraxil) and smallpox vaccine complications (VIGIV) were developed	Emergent BioSolutions/ National Institute of Allergy and Infectious Diseases (NIAID)	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)		Phase 2 trials begin ~ August 2020		TechCrunch Emergent Biosolutions Pink Sheet Emergent BioSolutions
33	Horse plasma product (COVID-EIG)	N/A	Same equine hyperimmune platform as FDA-approved botulism anti-toxin (BAT) is produced	Emergent BioSolutions	Pre-clinical			Phase 2 trials begin ~ August 2020		TechCrunch Emergent Biosolutions Pink Sheet Emergent BioSolutions

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
34	Convalescent plasma (blood plasma from recovered patients)	N/A		Multiple global research sponsors, including New York State Department of Health, Johns Hopkins University*	Clinical/Expanded Access*	Bloomberg Philanthropies and the State of Maryland (to Johns Hopkins University)*	NCT04321421 (Foundation IRCCS San Matteo Hospital) NCT04292340 (Shanghai Public Health Clinical Center) NCT04316728 (Centro Studi Internazionali, Italy) NCT04338360 (Mayo Clinic) (Expanded Access)*	New York State Department of Health trial begins March 2020	medRxiv JAMA Network medRxiv JAMA Network	Politico Johns Hopkins University*
35	Antibodies from recovered COVID-19 patients	N/A		Tsinghua University/Third People's Hospital of Shenzhen/Brii Biosciences	Pre-clinical			Phase 1 trial begins Q3 2020		Tsinghua University press release End Points News
36	Polyclonal hyperimmune globulin (H-IG)	N/A		Grifols	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)				MedicalCountermeasures.gov
37	Antibodies from recovered COVID-19 patients	N/A		Grifols	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)				Grifols MedicalCountermeasures.gov
38	Antibodies from recovered COVID-19 patients	N/A		Amgen/Adaptive Biotechnologies	Pre-clinical					Amgen
39	Antibodies from recovered COVID-19 patients	N/A		Innovent Biologics	Pre-clinical					Endpoints News
40	Antibodies from recovered COVID-19 patients	N/A		Xbiotech/BioBridge Global	Pre-clinical					Xbiotech and BioBridge press release

* Indicates updated or new field

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
41*	Antibodies from recovered COVID-19 patients*	N/A*		Costa Rican Social Security Fund (CCSS)/The University of Costa Rica (UCR)/Clodomiro Picado Institute*	Pre-clinical*					MENAFN*
42*	SAB-185, Polyclonal hyperimmune globulin (H-IG)*	N/A*		CSL Behring/SAb Biotherapeutics*	Pre-clinical*	Biomedical Advanced Research and Development Authority (BARDA)*		Phase 1 starts early summer 2020*		CSL Behring* SAB Biotherapeutics*
43*	Non-viral gene therapy to produce monoclonal antibodies	N/A		Generation Bio/Vir Biotechnology	Pre-clinical					Generation Bio
44*	rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin), polyclonal antibodies	N/A		GigaGen	Pre-clinical					FierceBiotech
45*	IC14, recombinant chimeric anti-CD14 monoclonal antibody*	N/A*	Acute Respiratory Distress Syndrome*	Implicit Bioscience*	Expanded access*		NCT04346277 (Implicit Bioscience) (Expanded Access)*			

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
ANTIVIRALS										
46*	Favilavir/Favipiravir/T-705/ Avigan, licensed in Japan to treat influenza	N/A		Fujifilm Toyama Chemical/Zhejiang Hisun Pharmaceuticals/numerous trials with global research sponsors/ Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School	Clinical		NCT04303299 (Rajavithi Hospital) (Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine) NCT04310228 (Peking University First Hospital) (also tocilizumab + favipiravir) ChiCTR2000029548 (The First Affiliated Hospital, Zhejiang University School of Medicine) (Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir) ChiCTR2000029496 (Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd) (Novaferon, Kaletra, Novaferon+Kaletra) ChiCTR2000029544 (The First Hospital Affiliated to Zhejiang University's Medical School) (Baloxavir Marboxil, Favipiravir) ChiCTR2000030254 (Zhongnan Hospital of Wuhan University) NCT04336904 (Giuliano Rizzardini, ASST Fatebenefratelli Sacco)	Phase 3 trial in Japan started in March 2020; Phase 2 trial in US started April 2020	medRxiv	World Health Organization Clinical Trials Arena Pharmaceutical Technology BioCentury Guardian Fujifilm

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
46 (cont.)*	Favilavir/Favipiravir/T-705/Avigan, licensed in Japan to treat influenza	N/A		Fujifilm Toyama Chemical/Zhejiang Hisun Pharmaceuticals/numerous trials with global research sponsors/Brigham and Women's Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School	Clinical		NCT04333589 (Peking University First Hospital) NCT04345419 (Tanta University) (chloroquine; favipiravir; nitazoxanide; ivermectin; niclosamide)*	Phase 3 trial in Japan started in March 2020; Phase 2 trial in US started April 2020	medRxiv	World Health Organization Clinical Trials Arena Pharmaceutical Technology BioCentury Guardian Fujifilm
47*	Kaletra/Aluvia (lopinavir/ritonavir), HIV-1 protease inhibitor	FDA-approved since 2000, approved to treat HIV-1 infection		Global hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ritonavir with and without interferon beta); University of Oxford RECOVERY trial; REMAP-CAP global trial	Clinical	UK Government (University of Oxford RECOVERY trial)	NCT04303299 (Rajavithi Hospital) (Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine) NCT04255017 (Tongji Hospital) (Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) ChiCTR2000029548 (The First Affiliated Hospital, Zhejiang University School of Medicine) (Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir) ChiCTR2000029539 (Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) EudraCT 2020-000936-23, INSERM study (lopinavir/ritonavir; Rebif; remdesivir) NCT04307693 (Asan Medical Center) (Lopinavir/Ritonavir or Hydroxychloroquine)		New England Journal of Medicine medRxiv Chinese Journal of Infectious Diseases medRxiv	PhRMA Wall Street Journal Wall Street Journal Wall Street Journal Stat News UK Government REMAP-CAP RECOVERY Trial

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
47 (cont.)*	Kaletra/Aluvia (lopinavir/ritonavir), HIV-1 protease inhibitor						NCT04315948 (Institut National de la Santé Et de la Recherche Médicale, France) (remdesivir, lopinavir/ritonavir, interferon beta-1a, hydroxychloroquine) NCT04252885 (Guangzhou Eighth People's Hospital) (Lopinavir Plus Ritonavir; Arbidol) NCT04276688 (The University of Hong Kong) (Lopinavir/ritonavir; ribavirin; interferon beta-1B) NCT02735707 (MJM Bonten) (REMAP-CAP global trial) NCT04321993 (Lisa Barrett, Nova Scotia Health Authority) (lopinavir/ritonavir; hydroxychloroquine; baricitinib; sarilumab) 2020-001113-21 (RECOVERY Trial) (lopinavir-ritonavir; low-dose dexamethasone, hydroxychloroquine, azithromycin)			

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
48*	remdesivir, nucleotide analog	N/A	Treatment of Ebola	Gilead; World Health Organization SOLIDARITY trial; National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial	Clinical / Expanded Access		NCT04257656 (Capital Medical University), China study in patients with severe disease NCT04252664 (Capital Medical University), China study in patient with mild/moderate disease NCT04292730, Gilead study in patients with moderate disease NCT04292899, Gilead study in patients with severe disease NCT04280705, NIAID study EudraCT 2020-000936-23, INSERM study NCT04315948 (Institut National de la Santé Et de la Recherche Médicale, France) (remdesivir, lopinavir/ritonavir, interferon beta-1a, hydroxychloroquine) NCT04302766 (Intermediate-size population Expanded Access) NCT04323761 (Gilead Sciences) (Expanded Access)*	Gilead Phase 3 trial results expected April 2020 (severe disease) and May 2020 (moderate disease); NIAID trial results expected in May 2020*	New England Journal of Medicine New England Journal of Medicine	PhRMA Wall Street Journal PhRMA post on LinkedIn Stat News Seeking Alpha Gilead Endpoints News FierceBiotech Gilead press release*

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
49*	Prezcobix (darunavir, HIV-1 protease inhibitor/cobicistat, CYP3A inhibitor)	FDA-approved since 2015, approved to treat HIV-1 infection		Chinese hospital testing (Janssen)	Clinical		ChiCTR2000029541 (Zhongnan Hospital of Wuhan University) (darunavir/cobicistat; lopinavir/ritonavir + thymosin a1) NCT04252274 (Shanghai Public Health Clinical Center) NCT04303299 (Rajavithi Hospital) (Various combination of protease inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine) NCT04304053 (Fundacio Lluita Contra la SIDA) (prevention, darunavir/cobicistat or hydroxychloroquine)	Primary study ends August 2020		World Health Organization Wall Street Journal
50*	galidesivir	N/A	Treatment of yellow fever	BioCryst Pharmaceuticals	Clinical	National Institute of Allergy and Infectious Diseases (NIAID)	NCT03891420 (BioCryst Pharmaceuticals)*	Phase 1b to start April 2020*		Reuters BioCryst BioCryst
51*	Combination of ebastine, lopinavir, and interferon alpha	N/A		Mianyang Central Hospital	Clinical		ChiCTR2000030535 (Mianyang Central Hospital)	Primary trial ends March 31, 2020		BioCentury
52*	Ganovo (danoprevir), hepatitis C virus NS3 protease inhibitor; ritonavir; interferon, approved in China to treat Hepatitis C	N/A		Ascletris/Numerous trials with Chinese research sponsors	Clinical		NCT04291729 (The Ninth Hospital of Nanchang)		medRxiv	BioCentury ClinicalTrials.gov

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
53*	ASC09, HIV protease inhibitor	N/A	Treatment of HIV/AIDS	Asclepis Pharma	Clinical		NCT04261907 (The First Affiliated Hospital of Zhejiang University) (ASC09/Ritonavir and Lopinavir/Ritonavir) NCT04261270 (Tongji Hospital) (ASC09F+Oseltamivir; Ritonavir+Oseltamivir; Oseltamivir)	Primary trial ends May 2020		Nature Biotechnology Asclepis Pharma
54*	Truvada (emtricitabine and tenofovir, both HIV-1 nucleoside analog reverse transcriptase inhibitors)	FDA-approved since 2004, approved to treat and prevent HIV-1 infection		Gilead/Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital	Clinical		ChiCTR2000029468 (Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital)			World Health Organization
55*	Arbidol (umifenovir), licensed in Russia and China for treatment of respiratory viral infections	N/A		Pharmstandard/numerous trials with Chinese research sponsors	Clinical		NCT04252885 (Guangzhou Eighth People's Hospital) (Lopinavir Plus Ritonavir; Arbidol)		medRxiv Chinese Journal of Infectious Diseases medRxiv medRxiv medRxiv	World Health Organization BioCentury
56*	Xofluza (baloxavir marboxil), polymerase acidic endonuclease inhibitor	FDA-approved since 2018, approved to treat influenza		Roche/The First Affiliated Hospital of Zhejiang University Medical School	Clinical		ChiCTR2000029544 (The First Hospital Affiliated to Zhejiang University's Medical School) (Baloxavir Marboxil, Favipiravir) ChiCTR2000029548 (The First Affiliated Hospital, Zhejiang University School of Medicine) (Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir)			World Health Organization

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
57*	azvudine, reverse transcriptase inhibitor	N/A		Numerous trials with Chinese research sponsors	Clinical		ChiCTR2000030487 (He'nan Sincere Biotechnology Co., Ltd) ChiCTR2000030424 (He'nan Sincere Biotechnology Co., Ltd) ChiCTR2000029853 (People's Hospital of Guangshan County)			World Health Organization
58*	Vicromax, broad spectrum antiviral			ViralClear Pharmaceuticals	Pre-clinical					AP
59*	ISR-50	N/A		ISR Immune System Regulation	Pre-clinical					ISR Immune System Regulation
60*	Tamiflu (oseltamivir), neuraminidase inhibitor	FDA-approved since 1999, approved to treat and prevent influenza		Roche	Clinical		NCT04303299 (Rajavithi Hospital) (Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine) NCT04255017 (Tongji Hospital) (Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) NCT04261270 (Tongji Hospital) (ASC09F+Oseltamivir; Ritonavir+Oseltamivir; Oseltamivir)			
61*	antiviral Fc conjugates	N/A		Cidara Therapeutics	Pre-clinical					Cidara Therapeutics
62*	Antiviral compounds	N/A		Cocrystal Pharma	Pre-clinical					Cocrystal Pharma

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
63*	EIDD-2801, oral ribonucleoside analog	N/A		Ridgeback Biotherapeutics/Drug Innovation Ventures at Emory (DRIVE)*	Clinical			Phase 1 started April 2020*		Ridgeback Biotherapeutics press release Ridgeback Biotherapeutics press release Ridgeback Biotherapeutics press release*
64*	Virazole (ribavirin for inhalation solution)	FDA-approved since 1985, approved to treat lower respiratory tract infections due to RSV		Bausch Health	Clinical/ Compassionate Use					Bausch Health
65*	Antiviral drug combinations	Unknown		SCORE consortium (universities of Aix-Marseille, Leuven, Utrecht, Bern, and Lubeck), the Helmholtz Centre for Infection Research, and Janssen Pharmaceutica NV	Pre-clinical	EU Commission (Horizon 2020 Program)				Leiden University Medical Center
CELL-BASED THERAPIES										
66*	PLX cell product, placenta-based cell therapy	Unknown		Pluristem Therapeutics/BIH Center for Regenerative Therapy/Berlin Center for Advanced Therapies	Pre-clinical					Pharmaceutical Technology Pluristem Therapeutics

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
67*	Mesenchymal stem cells	Unknown		Numerous trials with global research sponsors	Clinical		ChiCTR2000029990 (Institute of Basic Medicine, Chinese Academy of Medical Sciences) NCT04315987 (Azidus Brasil) (NestCell®) NCT04302519 (CAR-T [Shanghai] Biotechnology Co., Ltd.) (Dental Pulp Mesenchymal Stem Cells) NCT04288102 (Beijing 302 Hospital/VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China) NCT04313322 (Stem Cells Arabia) (Wharton's Jelly-Mesenchymal Stem Cells) NCT04273646 (Wuhan Union Hospital, China/Wuhan Hamilton Bio-technology Co., Ltd, China) (Human Umbilical Cord Mesenchymal Stem Cells)		Aging and Disease ChinaXiv	BioCentury
68*	Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)	Unknown	Injuries, Pain, and Autoimmune, Vascular and Other Disease, including Inflammatory lung conditions, pneumonia, and chronic obstructive pulmonary disease (COPD)	Celltex	Expanded access					Celltex press release Celltex

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
69*	Ryonicil (remestemcel-L), allogenic mesenchymal stem cells	N/A		Mesoblast	Pre-clinical					FierceBiotech
70*	MultiStem, bone marrow stem cells		Acute Respiratory Distress Syndrome; Stroke	Athersys	Clinical					BioSpace
71*	Allogeneic T-cell therapies	N/A		AlloVir/Baylor College of Medicine	Pre-clinical					AlloVir FierceBiotech
72*	Natural killer cell-based therapy	N/A		GC LabCell/KLEO Pharmaceuticals	Pre-clinical			Begin Phase 1 by end of 2020		UPI Korea Biomedical Review
73*	CYNK-001, allogeneic, natural killer cell therapy	N/A	Various hematologic cancers and solid tumors	Celularity	Clinical			Phase 1/2 study to start in April 2020		Celularity press release
74*	CAP-1002, allogenic cardiosphere-derived cells*	N/A*	Duchenne muscular dystrophy*	Capricor Inc.*	Expanded access*		NCT04338347 (Capricor Inc.) (expanded access)*			Capricor Therapeutics press release*
RNA-BASED TREATMENTS										
75*	RNAi - testing 150 RNAs	N/A		Sirnaomics	Pre-clinical					NPR
76*	siRNA candidates	N/A		Vir Biotech/Alnylam Pharmaceuticals	Pre-clinical					Clinical Trials Arena Celularity press release Vir and Alnylam press release
77*	Ampligen; (rintatolimod)	N/A		AIM ImmunoTech/National Institute of Infectious Diseases in Japan	Pre-clinical					AIM Immunotech press release
78*	OT-101, a TGF-Beta antisense drug candidate	N/A	Various cancers	Mateon Therapeutics	Clinical					Clinical Trials Arena Mateon Therapeutics
79*	Inhaled mRNA	N/A		Neurimmune/Ethris	Pre-clinical			Phase 1 to start Q4 2020		Neurimmune

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
SCANNING COMPOUNDS TO REPURPOSE										
80*	Scanning library of antiviral compounds	N/A	N/A	Janssen Pharmaceutical Companies	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)				Johnson & Johnson PhRMA
81*	Scanning compounds to repurpose	N/A	N/A	Novartis	Pre-clinical					PhRMA
82*	Scanning antiviral compounds previously in development	N/A	N/A	Pfizer	Pre-clinical			Lead candidate (protease inhibitor) to start Phase 1 trial in Q3 2020		Pfizer PhRMA Pfizer
83*	Scanning compounds to repurpose	N/A	N/A	Merck	Pre-clinical					Wall Street Journal
84*	Repurposing antiviral drug candidates	N/A	N/A	Materia Medica/Cyclica	Pre-clinical					Cyclica press release
85*	Screening new drugs + library of antiviral compounds	N/A	N/A	Enanta Pharmaceuticals	Pre-clinical					FierceBiotech Enanta Pharmaceuticals
86*	Screening drug compounds	N/A	N/A	Southwest Research Institute	Pre-clinical					Clinical Trials Arena
87*	Scanning compounds to repurpose	N/A	N/A	Takeda	Pre-clinical					PhRMA
88*	Scanning compounds to repurpose	N/A	N/A	Queens University Belfast	Pre-clinical	UK Government				UK Government
89*	Scanning compound libraries	N/A	N/A	COVID-19 Therapeutics Accelerator (15 companies shared their compound libraries including BD, bioMérieux, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck [known as MSD outside the US and Canada], Merck KGaA, Novartis, Pfizer, and Sanofi)	Pre-clinical	Gates Foundation/ Wellcome/ Mastercard Impact Fund				Novartis press release Gates Foundation

90*	Artificial intelligence-based screening to identify repurposed drug combinations		N/A	Healx	Pre-clinical			Combinations will be ready for preclinical testing in May 2020		Healx press releas
91*	Identifying drugs to repurpose			The Castleman Disease Collaborative Network and the Center for Study & Treatment of Inflammatory Lymphadenopathies	Pre-clinical					Castleman Disease Collaborative Network

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
OTHERS										
92*	Methylprednisolone / ciclesonide/ hydrocortisone/ corticosteroids	FDA-approved since at least the 1950s, approved to treat many diseases, including anti-inflammatory conditions and some cancers		Numerous trials with research sponsors globally; University of Oxford RECOVERY trial; REMAP-CAP global trial	Clinical	UK Government (University of Oxford RECOVERY trial)	NCT04244591 (Peking Union Medical College Hospital) (methylprednisolone) NCT04263402 (Tongji Hospital) (Methylprednisolone) NCT04273321 (Beijing Chao Yang Hospital) (Methylprednisolone) ChiCTR2000029656 (Wuhan Pulmonary Hospital) (methylprednisolone) ChiCTR2000029386 (Chongqing Public Health Medical Center) (Methylprednisolone) NCT02735707 (MJM Bonten) (REMAP-CAP global trial; hydrocortisone) NCT04330586 (Korea University Guro Hospital) (ciclesonide) 2020-001113-21 (RECOVERY Trial) (lopinavir-ritonavir; low-dose dexamethasone, hydroxychloroquine, azithromycin)	Primary study ends April 2020 (Peking) / June 2020 (Tongji)	medRxiv medRxiv	World Health Organization UK Government REMAP-CAP REMAP-CAP RECOVERY Trial

Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
93*	Chloroquine/ Hydroxychloroquine, antimalarial	FDA-approved since 1949, approved to treat malaria (chloroquine), FDA-approved since at least 1955, approved to treat malaria, rheumatoid arthritis, and lupus (hydroxychloroquine)		Numerous trials with global research sponsors; University of Minnesota; University of Washington/New York University (hydroxychloroquine); University of Oxford; IHU-Méditerranée Infection and others; World Health Organization SOLIDARITY trial (chloroquine); New York State Department of Health (hydroxychloroquine with zithromax); Mahidol Oxford Tropical Medicine Research Unit (hydroxychloroquine and chloroquine); ORCHID Trial with National Heart, Lung, and Blood Institute (NHLBI)	Clinical / FDA issued an Emergency Use Authorization on March 28, 2020 (oral formulations of chloroquine phosphate and hdoxychloroquinine sulfate donated to the Strategic National Stockpile to treat adolescent and adult hospitalized patients with COVID-19 when a clinical trial is not available or feasible)	COVID-19 Treatment Accelerator (University of Washington/ New York University trial and Mahidol Oxford Tropical Medicine Research Unit trial); UK Government (University of Oxford RECOVERY trial)	NCT04261517 (Shanghai Public Health Clinical Center) (Hydroxychloroquine) NCT04303507 (University of Oxford) (chloroquine prevention study) NCT04303299 (Rajavithi Hospital) (Various combination of protease inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine) NCT04304053 (Fundacio Lluita Contra la SIDA) (prevention, darunavir/cobicistat or hydroxychloroquine) NCT04307693 (Asan Medical Center) (Lopinavir/Ritonavir or Hydroxychloroquine) NCT04316377 (University Hospital, Akershus) (Hydroxychloroquine) NCT04315948 (Institut National de la Santé Et de la Recherche Médicale, France) (remdesivir, lopinavir/ ritonavir, interferon beta-1a, hydroxychloroquine)	Results from the University of Washington/NYU trial expected in summer 2020	NCT04261517 (Shanghai Public Health Clinical Center) (Hydroxychloroquine) IHU-Méditerranée Infection Journal of ZheJiang University (Medical Sciences) medRxiv medRxiv medRxiv (ChiCTR2000029559) medRxiv medRxiv (NCT04323527) medRxiv medRxiv medRxiv medRxiv medRxiv ScienceDirect ISAC	World Health Organization BioCentury Endpoints News Stat News Politico Sandoz University of Washington Mastercard press release FDA RECOVERY Trial
Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources

93 (cont.)*	Chloroquine/ Hydroxychloroquine, antimalarial						NCT04321993 (Lisa Barrett, Nova Scotia Health Authority) (lopinavir/ritonavir; hydroxychloroquine; baricitinib; sarilumab) 2020-001113-21 (RECOVERY Trial) (lopinavir-ritonavir; low-dose dexamethasone, hydroxychloroquine, azithromycin) NCT04323527 (Fundação de Medicina Tropical Dr. Heitor Vieira Dourado) NCT04333732 (Washington University School of Medicine) NCT04332991 (Massachusetts General Hospital) (ORCHID trial, National Heart, Lung, and Blood Institute [NHLBI]) NCT04345419 (Tanta University) (chloroquine; favipiravir; nitazoxanide; ivermectin; niclosamide)* Over 22 trials registered in China		ScienceDirect medRxiv medRxiv*	
Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources

94*	Camostat mesylate, transmembrane protease serine 2 (TMPRSS2) inhibitor, approved in Japan to treat multiple conditions including pancreatitis	N/A		Leibniz Institute for Primate Research/University Göttingen and others	Clinical		NCT04321096 (University of Aarhus)			Nature Biotechnology bioRxiv Thailand Medical News Cell
95*	Jakafi/jakavi (ruxolitinib)	FDA-approved since 2011, approved to treat myelofibrosis, polycythemia vera, and acute graft-versus-host disease		Novartis /Incyte, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology/Incyte Corp	Clinical / Expanded Acces		ChiCTR2000029580 (Department of Hematology, Tongji Medical College, Huazhong University of Science and Technology) (ruxolitinib in combination with mesenchymal stem cells) NCT04334044 (Grupo Cooperativo de Hemopatías Malignas) NCT04331665 (University Health Network, Toronto) NCT04337359 (Novartis Pharmaceuticals) (Expanded Access)*			World Health Organization Novartis Incyte press release
Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources

96*	PegIntron, Sylatron, IntronA (peginterferon alfa-2b)	PegIntron - FDA-approved since 2001, approved to treat Hepatitis C; Sylatron - FDA-approved since 2001, approved for the adjuvant treatment of melanoma; Intron A - FDA-approved since 1986, approved to treat Hepatitis C and certain cancers		Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) (Schering)	Clinical					World Health Organization
97*	Novaferon, Nova, interferon, licensed in China for Hepatitis B	N/A		The First Affiliated Hospital of Zhejiang University Medical School	Clinical		ChiCTR2000029573 (The First Affiliated Hospital of Medical College of Zhejiang University) (antiviral therapy, Chinese medicine treatment, and Novaferon atomization) ChiCTR2000029496 (Hu'nan Haiyao hongxingtang Pharmaceutical Co., Ltd) (Novaferon, Kaletra, Novaferon+Kaletra)			World Health Organization
98*	Traumakine (interferon beta 1-a)	N/A		Faron Pharmaceuticals/REMAP-CAP global trial	Clinical		NCT02735707 (MJM Bonten) (REMAP-CAP global trial)	Added to REMAP-CAP trial		Faron Pharmaceuticals press release
99*	SNG001, inhaled formulation of interferon beta-1a	N/A	Asthma patients with cold or flu infection; COPD patients with viral infections	Synairgen / University of Southampton	Clinical			Phase 2 began in March 2020		pharmaphorum
100*	Peginterferon lambda		Hepatitis Delta	Eiger BioPharmaceuticals, Inc.	Clinical		NCT04331899 (Stanford University)	Phase 2 began in April 2020		Eiger BioPharmaceuticals press release Eiger BioPharmaceuticals
Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources

101*	Cerocal (ifenprodil), NP-120, an NDMA receptor glutamate receptor antagonist targeting Glu2NB	N/A	Idiopathic Pulmonary Fibrosis	Algernon Pharmaceuticals	Pre-clinical					Clinical Trials Arena Algernon Pharmaceuticals
102*	APN01; recombinant soluble human Angiotensin Converting Enzyme 2	N/A	Acute lung injury, Acute respiratory distress syndrome, Pulmonary arterial hypertension	University of British Columbia/Apeiron Biologics	Clinical	Austrian Government		Phase 2 began in April 2020		Clinical Trials Arena Apeiron Biologics Apeiron Biologics press release
103*	Brilacidin, a defensin mimetic	N/A	Oral Mucositis; Ulcerative Proctitis/Ulcerative Proctosigmoiditis; Acute Bacterial Skin and Skin Structure Infection	Innovation Pharmaceuticals	Clinical					Clinical Trials Arena Innovation Pharmaceuticals Innovation Pharmaceuticals
104*	BXT-25; glycoprotein	N/A		Bioxytran	Pre-clinical					Clinical Trials Arena
105*	Peptides targeting the NP protein	Unknown		CEL-SCI/University of Georgia Center for Vaccines and Immunology	Pre-clinical					Clinical Trials Arena CEL-SCI Corporation press release FierceBiotech BioSpace
106*	BIO-11006, inhaled peptide	N/A	Acute Respiratory Distress Syndrome; Non-Small Cell Lung Cancer; Chronic Obstructive Pulmonary Disease (COPD)	Biomarck Pharmaceuticals	Clinical					Biomarck Pharmaceuticals
107*	Gilenya (fingolimod), sphingosine 1-phosphate receptor modulator	FDA-approved since 2010, approved to treat multiple sclerosis		The First Affiliated Hospital of Fujian Medical University/Novartis	Clinical		NCT04280588 (First Affiliated Hospital of Fujian Medical University)	Primary trial ends July 2020		
108*	WP1122, glucose decoy prodrug (and related drug candidates)	N/A		Moleculin Biotech/University of Texas Medical Branch	Pre-clinical					FierceBiotech Moleculin
Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources

109*	Rebif (interferon beta-1a)	FDA-approved since 2002, approved to treat multiple sclerosis		Institut National de la Sante et de la Recherche Medicale (Merck KGaA)	Clinical		EudraCT 2020-000936-23, INSERM study (lopinavir/ritonavir; Rebif; remdesivir) NCT04315948 (Institut National de la Santé Et de la Recherche Médicale, France) (remdesivir, lopinavir/ritonavir, interferon beta-1a, hydroxychloroquine)			Merck KGaA press release
110*	nafamostat, approved in Japan to treat pancreatitis and other diseases	N/A		University of Tokyo/ National Center for Global Health and Medicine	Clinical			Trial starts April 2020		Bloomberg News
111*	A number of synthesized nanoviricide drug candidates	N/A		NanoViricides	Pre-clinical					Clinical Trials Arena NanoViricides Inc.
112*	losartan	FDA-approved since 1995, approved to treat hypertension and diabetic nephropathy		University of Minnesota	Clinical		NCT04312009 (University of Minnesota) (Losartan for Patients With COVID-19 Requiring Hospitalization) NCT04311177 (University of Minnesota) (Losartan for Patients With COVID-19 Not Requiring Hospitalization)			KARE TV
113*	Activase (alteplase), tissue plasminogen activator (tPA)	FDA-approved since 1987, approved to treat stroke, myocardial infarction, and pulmonary embolism		Beth Israel Deaconess, the University of Colorado Anschutz Medical Campus, and Denver Health (Genentech)	Compassionate Use					MIT News
Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources

114*	Leukine (sargramostim, rhu-Granulocyte macrophage colony stimulating factor)	FDA-approved since 1991, approved to shorten the time to neutrophil recovery and reduce the incidence of infections following chemotherapy, mobilize hematopoietic progenitor cells, accelerate myeloid reconstitution following bone marrow or cell transplantation, treat delayed neutrophil recovery or graft failure after bone marrow transplantation, and increase survival of radiation	Pulmonary conditions that affect alveolar macrophages (nebulized leukine); ARDS (IV leukine)	Partner Therapeutics	Clinical		NCT04326920 (University Hospital, Ghent)			Partner Therapeutics
115*	Kineret (anakinra), interleukin-1 receptor antagonist	FDA-approved since 2001, approved to treat rheumatoid arthritis and cryopyrin-associated periodic syndromes		Swedish Orphan Biovitrum/REMAP-CAP global trial	Clinical		NCT04324021 (Swedish Orphan Biovitrum) (Emapalumab; Anakinra) NCT02735707 (MJM Bonten) (REMAP-CAP global trial)			REMAP-CAP
116*	AT-001, aldose reductase inhibitor	N/A	Diabetic cardiomyopathy	Applied Therapeutics / numerous New York City hospitals	Clinical / Compassionate Use					Applied Therapeutics
117*	Aplidin (plitidepsin), approved in Australia to treat multiple myeloma			PharmaMar	Clinical					PharmaMar
118*	dipyridamole (Persantine), anticoagulant	FDA-approved since 1961, approved to prevent postoperative thromboembolic complications of cardiac valve replacement		Numerous Chinese hospitals	Clinical				medRxiv	
Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources

119*	recombinant human plasma gelsolin (rhu-pGSN)	N/A	Community-acquired pneumonia	BioAegis Therapeutics Inc.	Clinical					GlobeNewswire
120*	solnatide (synthetic molecule with a structure based on the lectin-like domain of human Tumour Necrosis Factor alpha)	N/A	Pneumonia, sepsis, ARDS, Primary Graft Dysfunction, and pulmonary dysfunctions	Apeptico	Clinical	EU Commission (Horizon 2020 Program)				APEPTICO
121*	Nitric oxide	FDA-approved since 1999, approved to improve oxygenation in neonates		Massachusetts General Hospital; University of British Columbia	Clinical		NCT04305457 (Massachusetts General Hospital) NCT04312243 (Massachusetts General Hospital) (prevention) NCT04306393 (Massachusetts General Hospital) NCT03331445 (University of British Columbia)			Newsweek
122*	PP-001	N/A	Severe eye diseases	Panoptes Pharma GmbH	Clinical					LISAvienna
123*	ARMS-1	N/A	Influenza prophylaxis	ARMS Pharmaceutical/UH Cleveland Medical Center/Case Western Reserve University	Clinical	Cleveland Foundation		Trial starts April 2020		University Hospitals press release
124*	PUL-042 inhalation solution	N/A	Prevent and treat respiratory complications in immunosuppressed cancer patients	Pulmotect	Clinical		NCT04312997 (Pulmotect, Inc.)			Pulmotect
Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources

125*	Olumiant (baricitinib), Janus kinase (JAK) inhibitor	FDA-approved since 2018, approved to treat rheumatoid arthritis		National Institute of Allergy and Infectious Disease (NIAID)'s Adaptive COVID-19 Treatment Trial; Nova Scotia Health Authority; Hospital of Prato; University of Colorado (Eli Lilly)	Clinical		NCT04321993 (Lisa Barrett, Nova Scotia Health Authority) (lopinavir/ritonavir; hydroxychloroquine; baricitinib; sarilumab) NCT04320277 (Hospital of Prato) NCT04340232 (University of Colorado, Denver) NCT04280705 (National Institute of Allergy and Infectious Diseases [NIAID]) (Adaptive COVID-19 Treatment Trial [ACTT])			Eli Lilly
126*	Xeljanz (tofacitinib), Janus kinase (JAK) inhibitor	FDA-approved since 2012, approved to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis		Pfizer	Clinical		NCT04332042 (Università Politecnica delle Marche)			Pfizer
127*	colchicine	N/A (but has been used in the US since the early 1800s, and FDA-approved in combination with probenecid, approved to treat gout)		Numerous research sponsors globally	Clinical		NCT04326790 (National and Kapodistrian University of Athens) NCT04328480 (Estudios Clínicos Latino América) NCT04322565 (Lucio Manenti, Azienda Ospedaliero-Universitaria di Parma) NCT04322682 (Montreal Heart Institute)			National Post
Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources

128*	low molecular weight heparin, anticoagulant	FDA-approved since at least 1993, approved to prevent blood clots and prevent/treat venous thromboembolism and myocardial infarction		Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Clinical					medRxiv
129*	LAU-7b (fenretinide)	N/A	Treat exaggerated inflammatory response in adult cystic fibrosis patients	Laurent Pharmaceuticals	Clinical			Phase 2 to start May 2020		Laurent Pharmaceuticals press release
130*	Xpovio (selinexor), oral, selective inhibitor of nuclear export (SINE) compound	FDA-approved since 2019, approved to treat multiple myeloma	Treat various cancers	Karyopharm Therapeutics	Clinical					Karyopharm Therapeutics
131*	BLD-2660, synthetic small molecule inhibitor of calpain (CAPN) 1, 2, and 9	N/A		Blade Therapeutics	Clinical		NCT04334460 (Blade Therapeutics)			
132*	Calquence (acalabrutinib), Bruton's tyrosine kinase (BTK) inhibitor	FDA-approved since 2017, approved to treat mantle cell lymphoma and chronic lymphocytic leukemia		AstraZeneca	Clinical					AstraZeneca
133*	CD24Fc, biological immunomodulator (nonpolymorphic regions of CD24 attached to the Fc region of human IgG1)	N/A	Graft versus Host Disease	Oncolmmune	Clinical					
134*	Aviptadil, synthetic form of Vasoactive Intestinal Polypeptide	N/A	Sarcoid, Pulmonary Fibrosis, Bronchospasm, Erectile Dysfunction, and Acute Respiratory Distress Syndrome (ARDS)	NeuroRx/Relief Therapeutics	Clinical					NeuroRx
135*	vazegepant, CGRP receptor antagonist		Acute migraine	Biohaven/Thomas Jefferson University	Clinical			Phase 2 to start April 2020		Biohaven Pharmaceuticals Endpoints News
Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources

136*	CM4620-IE, calcium release-activated calcium (CRAC) channel inhibitor		Pancreatitis	CalciMedica	Clinical			Phase 2 started in April 2020		Endpoints News CalciMedica
137*	ivermectin*	FDA-approved since 1996, approved to treat intestinal parasites and head lice infestations*		University of Utah/Surgisphere Corp; University of Baghdad; Tanta University*	Clinical*		NCT04343092 (University of Baghdad)* NCT04345419 (Tanta University) (chloroquine; favipiravir; nitazoxanide; ivermectin; niclosamide)*			SSRN*
138*	EPAAspire, oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules*	N/A*	Familial adenomatous polyposis*	KD Pharma/SLA Pharma*	Clinical*					KD Pharma Group and SLA Pharma press release*
DEVICES										
139*	CytoSorb (blood purification device, extracorporeal cytokine adsorber)	N/A		CytoSorbents Corporation	FDA issued an Emergency Use Authorization on April 10, 2020/Clinical/Compassionate Use		NCT04324528 (Dr. Alexander Supady) ChiCTR2000030475 (Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College)		NCT04344080 (Universitätsklinikum Hamburg-Eppendorf)	CytoSorbents Corporation press release FDA
140*	Extracorporeal blood purification (EBP) devices			Terumo BCT Inc/Marker Therapeutics AG	FDA issued an Emergency Use Authorization on April 9, 2020					FDA
141*	INOpulse			Bellerophon	Compassionate Use					Bellerophon Therapeutics
Number	Type of Product - Treatment	FDA-Approved Indications (Treatments)	Clinical Trials Ongoing for Other Diseases	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
DORMANT/DISCONTINUED										

1	Washed microbiota transplantation	Unknown		The Second Hospital of Nanjing Medical University	Clinical		NCT04251767 (The Second Hospital of Nanjing Medical University) (Washed Microbiota Transplantation for Patients With 2019-nCoV Infection)		Study stopped before recruitment	BioCentury
2	Recombinant ACE2 (angiotensin-converting enzyme 2)	Unknown		The First Affiliated Hospital of Guangzhou Medical University	Clinical		NCT04287686 (The First Affiliated Hospital of Guangzhou Medical University) (Recombinant Human Angiotensin-converting Enzyme 2 [rhACE2] as a Treatment for Patients With COVID-19)		Study stopped before recruitment	BioCentury



COVID-19 Treatment and Vaccine Tracker

This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another, but simply a list of all treatments and vaccines currently in development.

VACCINES

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
1	DNA plasmid; INO-4800	Same platform as vaccine candidates for Lassa, Nipah, HIV, Filovirus, HPV, cancer indications, Zika, and Hepatitis B	Inovio Pharmaceuticals/Beijing Advaccine Biotechnology	Clinical	Coalition for Epidemic Preparedness (CEPI)/Gates Foundation	NCT04336410 (Inovio Pharmaceuticals)	Started Phase 1 April 2020; initial data expected late summer 2020		World Health Organization MarketWatch BioAegis Therapeutics INOVIO
2	DNA		Takis/Applied DNA Sciences/Evvivax	Pre-clinical			Preclinical results expected in April 2020; Phase 1 to start in fall 2020		World Health Organization Takis
3	DNA plasmid		OPENCORONA - Cobra Biologics/Karolinska Institute	Pre-clinical	European Commission (Horizon 2020 Program)		Phase 1 to start in 2020		BioSpace
4	DNA plasmid		Osaka University/AnGes/Takara Bio	Pre-clinical					World Health Organization
5	DNA plasmid		Zydus Cadila	Pre-clinical					World Health Organization
6	DNA plasmid, needle-free delivery	Same platform as vaccine candidates for SARS	Immunomic Therapeutics/EpiVax/PharmaJet	Pre-clinical					World Health Organization
7	Inactivated (formaldehyde-inactivated + alum)	Same platform as vaccine candidates for SARS	Sinovac	Pre-clinical					World Health Organization
8	Inactivated		Beijing Institute of Biological Products/Wuhan Institute of Biological Products	Pre-clinical					World Health Organization
9	Inactivated		Osaka University/BIKEN/NIBIOHN	Pre-clinical					World Health Organization

LEGEND

CCHF = Crimean-Congo Haemorrhagic Fever	HIV = Human Immunodeficiency Virus	NIPV = Nipah Virus	TB = Tuberculosis
CHIKV = Chikungunya Virus	HPV = Human Papilloma Virus	NORV = Norovirus	VEE = Venezuelan Equine Encephalitis Virus
DengV = Dengue Virus	Inf = Influenza	RABV = Rabies Virus	VZV = Varicella Vaccine (Chickenpox)
FMD = Foot and Mouth Disease	LASV = Lassa Fever Virus	RSV = Respiratory Syncytial Virus	YFV = Yellow Fever Virus
EBOV = Ebola Virus	MARV = Marburg Virus	RVF = Rift Valley Fever	ZIKV = Zika Virus
HAV = Hepatitis A Virus	MenB = Meningitis B	SARS = Severe Acute Respiratory Syndrome	
HBV = Hepatitis B Virus	MERS = Middle East Respiratory Syndrome	SIV = Simian Immunodeficiency Virus	

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
10	Deoptimized live attenuated virus	Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV	Codagenix/Serum Institute of India	Pre-clinical			Animal data in summer 2020		World Health Organization Indian Express
11	Replicating viral vector, influenza vector expressing RBD	Same platform as vaccine candidates for MERS	The University of Hong Kong	Pre-clinical	Coalition for Epidemic Preparedness (CEPI)				World Health Organization Coalition for Epidemic Preparedness World Health Organization
12	CoroFlu, self-limiting influenza virus	Same platform as vaccine candidates for influenza	University of Wisconsin-Madison / FluGen/ Bharat Biotech	Pre-clinical			Start Phase 1 trial in fall 2020		Press release from the collaboration
13	Non-replicating viral vector; MVA encoded VLP	Same platform as vaccine candidates for LASV, EBOV, MARV, HIV	GeoVax/BravoVax	Pre-clinical					World Health Organization GeoVax GeoVax
14	Non-replicating viral vector; Ad26 (alone or with MVA boost)	Same platform as vaccine candidates for Ebola, HIV, RSV	Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)		Start Phase 1 in September 2020		World Health Organization Johnson & Johnson Johnson & Johnson FierceBiotech Johnson & Johnson press release
15	Non-replicating viral vector; ChAdOx1	Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague	Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, and HalixBV	Clinical	Coalition for Epidemic Preparedness (CEPI)/UK Government	NCT04324606 (University of Oxford)	Animal trials begin March 2020, Phase 1 begins April 2020		World Health Organization Guardian Fierce Biotech World Health Organization PharmaTimes
16	Non-replicating viral vector	Same platform as vaccine candidates for many pathogens	DZIF - German Center for Infection Research	Pre-clinical					World Health Organization
17	AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein	Same platform as vaccine candidates for influenza	Altimune/University of Alabama at Birmingham	Pre-clinical			Phase 1 trial to begin Q3 2020		World Health Organization Altimune press release Altimune
18	Non-replicating viral vector; Ad5 S (GREVAX™ platform)	Same platform as vaccine candidates for MERS	Greffex	Pre-clinical					World Health Organization Greffex

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
19	Non-replicating viral vector; Oral Vaccine platform	Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE	Vaxart/Emergent BioSolutions	Pre-clinical			Phase 1 trial to begin in the second half of 2020		World Health Organization Vaxart press release Emergent BioSolutions
20	Non-replicating viral vector, MVA expressing structural proteins	Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania	Centro Nacional Biotecnologia (CNB-CSIC), Spain	Pre-clinical					World Health Organization
21	Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)	Same platform as vaccine candidates for EBOV	CanSino Biologics/Beijing Institute of Biotechnology	Clinical		NCT04313127 (CanSino Biologics Inc.)	Phase 2 started April 2020*	ChiCTR2000030906 (Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China) (Phase 1) ChiCTR2000031781 (Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China) (Phase 2)	World Health Organization FiercePharma CanSino Biologics announcement Xinhua*
22	Protein subunit, capsid-lide particle (CLP)	Same platform as vaccine candidates for HPV	PREVENT-nCoV consortium (AdaptVac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, Wageningen University)	Pre-clinical	European Commission (Horizon 2020 Program)		Phase 1 to begin by February 2021		AdaptVac World Health Organization ExpreS2ion press release
23	Protein subunit, drosophila S2 insect cell expression system VLPs		ExpreS2ion	Pre-clinical					World Health Organization
24	Protein subunit; S protein		WRAIR/USAMRIID	Pre-clinical					World Health Organization

* Indicates updated or new field

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
25	Protein subunit, S protein + adjuvant	Same platform as vaccine candidates for Influenza	National Institute of Infectious Disease, Japan	Pre-clinical					World Health Organization
26	Protein subunit, VLP-recombinant protein + adjuvant		Osaka University/BIKEN/National Institutes of Biomedical Innovation, Japan	Pre-clinical					World Health Organization
27	Protein subunit, native like trimeric subunit spike protein	Same platform as vaccine candidates for HIV, RSV, Influenza	Clover Biopharmaceuticals Inc./GSK/Dynavax	Pre-clinical					World Health Organization World Health Organization
28	Protein subunit; peptide		Vaxil Bio	Pre-clinical					World Health Organization
29	Protein subunit; adjuvanted protein subunit (RBD)		Biological E Ltd	Pre-clinical					World Health Organization
30	Protein subunit; S protein		AJ Vaccines	Pre-clinical					World Health Organization
31	Protein subunit; S protein		Vaxine Pty Ltd/ Flinders University / Oracle	Pre-clinical					Flinders University press release
32	Protein subunit; li-Key peptide	Same platform as vaccine candidates for HIV, SARS-CoV, Influenza	Generex/EpiVax	Pre-clinical					World Health Organization Generex press release EpiVax
33	Protein subunit; S protein	Same platform as vaccine candidates for Inf H7N9	EpiVax/University of Georgia	Pre-clinical					World Health Organization EpiVax
34	PittCoVacc, Protein subunit, microneedle arrays S1 subunit	Same platform as vaccine candidates for MERS	University of Pittsburgh	Pre-clinical			Phase 1 to start as early as June 2020		University of Pittsburgh press release EBioMedicine World Health Organization
35	Protein subunit; S protein	Influenza, Ebola	University of Cambridge/DIOSynVax	Pre-clinical			Phase 1 to start as early as June 2020		University of Cambridge
36	Protein subunit; COVID-19 XWG-03 truncated Spike proteins	Same platform as vaccine candidates for HPV	Innovax/Xiamen University/GSK	Pre-clinical					FierceBiotech World Health Organization

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
37	Protein subunit; S protein, baculovirus production	Same platform as vaccine candidates for Influenza, SARS-CoV (FDA-approved vaccine)	Sanofi Pasteur/GSK	Pre-clinical	Biomedical Advanced Research and Development Authority (BARDA)		Start Phase 1 in second half of 2020		World Health Organization Sanofi Stat News MarketWatch Sanofi
38	NVX-CoV2373; Protein subunit; Full length S trimers/nanoparticle + Matrix M	Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV	Novavax/Emergent BioSolutions	Pre-clinical	Coalition for Epidemic Preparedness (CEPI)		Start Phase 1 in May 2020		World Health Organization Emergent BioSolutions Endpoints News
39	Protein subunit (gp-96 backbone)	Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika	Heat Biologics (Zolovax) /University of Miami	Pre-clinical					World Health Organization Clinical Trials Arena Heat Biologics
40	Protein subunit; molecular clamp stabilized Spike protein	Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa	University of Queensland/GSK/ Dynavax	Pre-clinical	Coalition for Epidemic Preparedness (CEPI)/ Queensland Government/ Federal Government (Australia)/Paul Ramsay Foundation				World Health Organization ABC News Australia Dynavax World Health Organization
41	Protein subunit; S1 or RBD protein	Same platform as vaccine candidates for SARS	Baylor College of Medicine	Pre-clinical					World Health Organization
42	Protein subunit; Subunit protein, plant produced		iBio/CC-Pharming	Pre-clinical					World Health Organization
43	Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)		St. Petersburg Scientific Research Institute of Vaccines and Serums	Pre-clinical					World Health Organization
44	Protein subunit, adjuvanted microsphere peptide		VIDO-InterVac, University of Saskatchewan	Pre-clinical	The Government of Saskatchewan and the Canadian Federal Government		Animal testing results expected in April 2020		World Health Organization World Health Organization Government of Saskatchewan
45	Protein subunit, peptide	Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer	Flow Pharma	Pre-clinical					World Health Organization

* Indicates updated or new field

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
46	Protein subunit, synthetic long peptide vaccine candidate for S and M proteins		OncoGen	Pre-clinical					World Health Organization
47	DPX-COVID-19, protein subunit, lipid-based delivery platform	Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax	IMV, Inc. / Canadian Center for Vaccinology at Dalhousie University/ Izaak Walton Killam Health Center/ Nova Scotia Health Authority; Canadian Immunization Research Network / University of Laval / Global Urgent and Advanced Research and Development in Canada	Pre-clinical			Start Phase 1 testing by summer 2020		IMV, Inc. IMV, Inc.
48	Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein		VBI Vaccines / National Research Council of Canada	Pre-clinical			Start Phase 1 testing by end of 2020		VBI Vaccines press release
49	Replicating viral vector; measles vector		Zydus Cadila	Pre-clinical					World Health Organization
50	Replicating viral vector; measles vector	Same platform as vaccine candidates for West Nile, CHIKV, Ebola, Lassa, Zika, MERS	Institut Pasteur/Themis/University of Pittsburgh	Pre-clinical	Coalition for Epidemic Preparedness (CEPI)		Start animal testing in April 2020		World Health Organization University of Pittsburgh Medical Center Coalition for Epidemic Preparedness
51	Live attenuated virus, measles virus	Same platform as vaccine candidates for Zika, H7N9, CHIKV	DZIF - German Center for Infection Research	Pre-clinical					World Health Organization
52	Replicating viral vector; horsepox vector; TNX-1800	Same platform as vaccine candidates for smallpox, monkeypox	Tonix Pharma/Southern Research	Pre-clinical					World Health Organization Tonix Pharmaceuticals press release
53	Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)		BIOCAD/IEM	Pre-clinical					World Health Organization
54	Replicating viral vector, VSV vector expressing S protein	Same platform as vaccine candidates for Ebola, Marburg, Lassa	IAVI/ Batavia	Pre-clinical					World Health Organization

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
55	RNA; LNP-encapsulated mRNA cocktail encoding VLP		Fudan University/Shanghai JiaoTong University/RNACure Biopharma	Pre-clinical					World Health Organization
56	RNA; LNP-encapsulated mRNA cocktail encoding RBD		Fudan University/Shanghai JiaoTong University/RNACure Biopharma	Pre-clinical					World Health Organization
57	RNA; Replicating defective SARS-CoV-2 derived RNAs		Centro Nacional Biotecnologia (CNB-CSIC), Spain	Pre-clinical					World Health Organization
58	RNA; LNP-encapsulated mRNA	Same platform as vaccine candidates for MERS	University of Tokyo/ Daiichi-Sankyo	Pre-clinical					World Health Organization
59	RNA; mRNA		China CDC/Tongji University/Stermina	Pre-clinical					World Health Organization
60	RNA; LNP-encapsulated mRNA (mRNA 1273)	Same platform as vaccine candidates for multiple candidates	Moderna/NIAID	Clinical	Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA)	NCT04283461 (National Institute of Allergy and Infectious Diseases)	Phase 1 started March 2020, study ends June 2021		World Health Organization Wall Street Journal MarketWatch ClinicalTrials.gov
61	LUNAR-COV19; RNA; mRNA	Same platform as vaccine candidates for multiple candidates	Arcturus/Duke-NUS	Pre-clinical			Start Phase 1 in summer 2020		World Health Organization Arcturus Therapeutics Arcturus Therapeutics
62	RNA; saRNA	Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV	Imperial College London	Pre-clinical			Start Phase 1 in summer 2020		World Health Organization Imperial College London
63	RNA; mRNA	Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV	CureVac	Pre-clinical	Coalition for Epidemic Preparedness (CEPI); European Commission		Start Phase 1 in June 2020		World Health Organization Labiotech.eu
64	RNA; BNT162		BioNTech/Fosun Pharma/Pfizer	Pre-clinical			Start Phase 1 late April 2020		FierceBiotech Endpoints News World Health Organization
65	RNA; liposome-encapsulated mRNA	Same platform as vaccine candidates for cancer	BIOCAD	Pre-clinical			Animal studies begin in April 2020		BIOCAD
66	RNA; mRNA		Sanofi Pasteur/ Translate Bio	Pre-clinical					Translate Bio

* Indicates updated or new field

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
67	RNA; mRNA (cross-strain protective COV-2 mRNA) vaccine for high-risk populations		eTheRNA Immunotherapies/EpiVax/Nexelis/REPROCELL/Centre for the Evaluation of Vaccination of the University of Antwerp	Pre-clinical			Start Phase 1 early 2021		EpiVax
68	RNA		GeneOne Life Science/Houston Methodist	Pre-clinical					Houston Methodist
69	VLP; virus-like particle, based on RBD displayed on virus-like particle		Saiba GmbH	Pre-clinical					World Health Organization
70	VLP; plant-derived VLP	Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer	Medicago Inc.	Pre-clinical			Start Phase 1 in July/August 2020		World Health Organization Medicago press release
71	VLP; ADDomer™ multipeptide display		Imphoron Ltd/Bristol University's Max Planck Centre	Pre-clinical					World Health Organization University of Bristol
72	Gene-encoded antibody vaccine, non-viral nanoparticle delivery		SmartPharm Therapeutics/Sorrento Therapeutics	Pre-clinical					SmartPharm Therapeutics
73	Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)		HaloVax (Voltron Therapeutics)/The Vaccine & Immunotherapy Center at the Massachusetts General Hospital	Pre-clinical			Animal study results by October 2020		Voltron Therapeutics press release
74	LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes		Shenzhen Geno-Immune Medical Institute	Clinical		NCT04276896 (Shenzhen Geno-Immune Medical Institute)			Nature

Number	Type of Vaccine	Related Use/Platform	Developer/Researcher	Current Stage of Development	Funding Sources	Clinical Trials for COVID-19	Anticipated Next Steps Timing	Published Results	Sources
75	Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins		Shenzhen Geno-Immune Medical Institute	Clinical		NCT04299724 (Shenzhen Geno-Immune Medical Institute)			Nature
76	ISR-50		ISR Immune System Regulation	Pre-clinical			Animal study results expected in Q2 2020, Phase 1 begins Q4 2020		ISR Immune System Regulation
77	Unknown		ImmunoPrecise	Pre-clinical					World Health Organization
78	Unknown		MIGAL Galilee Research Institute	Pre-clinical					World Health Organization
79	Unknown		Doherty Institute	Pre-clinical					World Health Organization
80	Unknown		Tulane University	Pre-clinical					World Health Organization Clinical Trials Arena
81	Unknown		SK Biosciences	Pre-clinical			Phase 1 begins as early as September 2020		UPI
82	Unknown		Vir Biotechnology/GSK	Pre-clinical					Vir Biotechnology
83	Unknown		Precision Vaccines Program at Boston Children's Hospital	Pre-clinical					Scientific American
84	Unknown, tobacco plant technology		Kentucky BioProcessing (British American Tobacco)	Pre-clinical					BAT
85	Unknown		ReiThera	Pre-clinical					World Health Organization
86	Unknown		BioNet Asia	Pre-clinical					World Health Organization